Literature DB >> 12807847

The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.

I Raymond1, B A Groenning, P R Hildebrandt, J C Nilsson, M Baumann, J Trawinski, F Pedersen.   

Abstract

OBJECTIVE: To identify potentially confounding variables for the interpretation of plasma N-terminal pro brain natriuretic peptide (NT-proBNP).
DESIGN: Randomly selected subjects filled in a heart failure questionnaire and underwent pulse and blood pressure measurements, ECG, echocardiography, and blood sampling.
SETTING: Subjects were recruited from four Copenhagen general practices located in the same urban area and were examined in a Copenhagen University Hospital. PATIENTS: 382 women and 290 men in four age groups: 50-59 years (n = 174); 60-69 years (n = 204); 70-79 years (n = 174); and > 80 years (n = 120). MAIN OUTCOME MEASURES: Associations between the plasma concentration of NT-proBNP and a range of clinical variables.
RESULTS: In the undivided study sample, female sex (p < 0.0001), greater age (p < 0.0001), increasing dyspnoea (p = 0.0001), diabetes mellitus (p = 0.01), valvar heart disease (p = 0.002), low heart rate (p < 0.0001), left ventricular ejection fraction < or = 45% (p < 0.0001), abnormal ECG (p < 0.0001), high log10[plasma creatinine] (p = 0.0009), low log10[plasma glycosylated haemoglobin A1c] (p = 0.0004), and high log10[urine albumin] (p < 0.0001) were independently associated with a high plasma log10[plasma NT-proBNP] by multiple linear regression analysis.
CONCLUSIONS: A single reference interval for the normal value of NT-proBNP is unlikely to suffice. There are several confounders for the interpretation of a given NT-proBNP concentration and at the very least adjustment should be made for the independent effects of age and sex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807847      PMCID: PMC1767734          DOI: 10.1136/heart.89.7.745

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  33 in total

1.  Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction.

Authors:  P F Downie; S Talwar; I B Squire; J E Davies; D B Barnett; L L Ng
Journal:  Clin Sci (Lond)       Date:  1999-09       Impact factor: 6.124

2.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

3.  Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice.

Authors:  O W Nielsen; J Hilden; J F Hansen
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

4.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

5.  Clinical criteria and biochemical markers for the detection of systolic dysfunction.

Authors:  K Yamamoto; J C Burnett; E A Bermudez; M Jougasaki; K R Bailey; M M Redfield
Journal:  J Card Fail       Date:  2000-09       Impact factor: 5.712

6.  Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.

Authors:  A S Maisel; J Koon; P Krishnaswamy; R Kazenegra; P Clopton; N Gardetto; R Morrisey; A Garcia; A Chiu; A De Maria
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

7.  Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis.

Authors:  S Talwar; P F Downie; I B Squire; J E Davies; D B Barnett; L L Ng
Journal:  Eur J Heart Fail       Date:  2001-01       Impact factor: 15.534

8.  Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?

Authors:  H Sayama; Y Nakamura; N Saito; M Kinoshita
Journal:  Coron Artery Dis       Date:  1999-10       Impact factor: 1.439

9.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.

Authors:  Q Dao; P Krishnaswamy; R Kazanegra; A Harrison; R Amirnovin; L Lenert; P Clopton; J Alberto; P Hlavin; A S Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

10.  Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension.

Authors:  V Raizada; K Thakore; W Luo; P G McGuire
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

View more
  73 in total

1.  Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children.

Authors:  L Schwachtgen; M Herrmann; T Georg; P Schwarz; N Marx; A Lindinger
Journal:  Z Kardiol       Date:  2005-06

2.  Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.

Authors:  P Gaede; P Hildebrandt; G Hess; H-H Parving; O Pedersen
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

3.  N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis?

Authors:  Thomas Häupl; Gerd R Burmester; Evangelos Giannitsis; Thorsten Rohrlach; Eberhard Spanuth; Hans Parsch; Kay Brune
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

4.  The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.

Authors:  Hyo Jin Choi; Young Kee Shin; Hyun Joo Lee; Joo Young Kee; Dong Woo Shin; Eun Young Lee; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2007-09-25       Impact factor: 2.980

5.  What Is the Meaning of Increased Myocardial Injury Enzymes during Hemodialysis? A Tissue Doppler Imaging Study.

Authors:  Gürsel Yildiz; Mansur Kayataş; Ferhan Candan; Mehmet Birhan Yilmaz; Ali Zorlu; Savaş Sarikaya
Journal:  Cardiorenal Med       Date:  2013-06-25       Impact factor: 2.041

Review 6.  Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

Authors:  Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

7.  Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Authors:  Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2018-06-01       Impact factor: 15.534

8.  Marked decrease in BNP levels in 2 related patients with reversible dilated cardiomyopathy.

Authors:  Ikuo Misumi; Kazuteru Fujimoto; Yuji Miyao; Mitsuhiro Matsumoto; Taku Rokutanda; Yousuke Hanaoka; Koichi Kaikita; Megumi Yamamuro; Seigo Sugiyama; Hisao Ogawa
Journal:  J Cardiol Cases       Date:  2011-11-27

9.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

Review 10.  Natriuretic peptide-guided therapy: further research required for still-unresolved issues.

Authors:  R De Vecchis; C Esposito; S Cantatrione
Journal:  Herz       Date:  2013-04-17       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.